CHORUS: A multi-centre double-blind randomised placebo-controlled group-sequential superiority trial to assess the effectiveness and cost-effectiveness of oral Corticosteroids in patients witH fibrOtic hypeRsensitivity pneUmonitiS (CHORUS)

Research summary

Double-blind,randomised (1:1) placebo-controlled,multi-centre,group-sequential,superiority trial,with internal pilot phase and parallel health economic evaluation. To assess the effectiveness of 26 weeks of treatment with prednisolone vs placebo on disease progression,as measured by the pulmonary function test,forced vital capacity. The change in absolute forced vital capacity (FVC) between baseline and 26 weeks post-randomisation will be compared in patients recently diagnosed with fibrotic hypersensitivity pneumonitis (FHP) and treated with daily prednisolone vs placebo in adults diagnosed with fibrotic hypersensitivity pneumonitis (FHP) within the last 6 months,and not previously/currently treated for FHP with prednisolone.

Principal Investigator

Yvonne West

Contact us

Email: samantha.chilcott@ndm.ox.ac.uk

IRAS number

1010739